Valuation: Laboratorios Richmond S.A.C.I.F.

Market Cap 105B 68.52M 61.36M 56.45M 51.14M 95.6M 6.51B 97.39M 673M 270M 3.42B 257M 252M 10.79B P/E 2024
6.08x
P/E 2025 51.6x
Enterprise Value 336B 219M 196M 180M 163M 305M 20.77B 311M 2.15B 863M 10.93B 821M 803M 34.45B EV / Sales 2024
3.04x
EV / Sales 2025 3.08x
Free-Float
17.54%
Yield 2024
1.5%
Yield 2025 -
08-06 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
05-11 Laboratorios Richmond S.A.C.I.F. announces Annual dividend, payable on May 15, 2026 CI
05-07 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
03-06 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
11-06 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
07/08/25 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 CI
09/05/25 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the First Quarter Ended March 31, 2025 CI
08/05/25 Laboratorios Richmond S.A.C.I.F. announces Annual dividend, payable on May 15, 2025 CI
08/03/25 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Full Year Ended December 31, 2024 CI
06/11/24 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 CI
13/08/24 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 CI
06/05/24 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
11/03/24 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
1 day+0.38%
1 week-3.33%
1 month-6.12%
3 months-15.81%
6 months-20.18%
Current year-33.92%
1 week 1,290
Extreme 1290
1,390
1 month 1,290
Extreme 1290
1,580
Current year 1,290
Extreme 1290
2,130
1 year 1,290
Extreme 1290
2,300
3 years 595.5
Extreme 595.5
2,300
5 years 215
Extreme 215
2,300
10 years 24.8
Extreme 24.8
2,300
Manager TitleAgeSince
President - -
General Counsel - 29/04/2025
Corporate Officer/Principal - 29/04/2025
Director TitleAgeSince
Director/Board Member - -
Director/Board Member - -
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
+0.38%-3.33%-18.18%+94.78% 68.52M
+3.19%+11.31%+64.28%+155.66% 1,263B
-0.73%+3.56%+44.65%+83.74% 658B
+1.41%+3.24%+35.25%+106.98% 521B
-1.33%+0.30%+53.26%+67.00% 391B
+2.18%+2.93%+73.90%+45.38% 369B
-1.31%+3.59%+32.72%+55.99% 307B
-0.56%+8.12%+12.41%+34.12% 290B
+1.15%+6.09%+56.15%+78.66% 252B
+3.06%+9.38%+42.48%+112.84% 212B
Average +0.27%+5.19%+39.69%+83.51% 426.2B
Weighted average by Cap. +0.26%+6.60%+50.16%+98.80%

Financials

2024 2025
Net sales 91.79B 59.68M 53.45M 49.17M 44.55M 83.28M 5.67B 84.83M 586M 235M 2.98B 224M 219M 9.4B 127B 82.4M 73.79M 67.88M 61.5M 115M 7.82B 117M 809M 325M 4.12B 309M 303M 12.98B
Net income 23.85B 15.5M 13.89M 12.77M 11.57M 21.63M 1.47B 22.04M 152M 61.14M 774M 58.18M 56.95M 2.44B 3.09B 2.01M 1.8M 1.65M 1.5M 2.8M 191M 2.85M 19.72M 7.92M 100M 7.53M 7.37M 316M
Net Debt 134B 86.9M 77.82M 71.59M 64.86M 121M 8.25B 124M 854M 343M 4.34B 326M 319M 13.69B 231B 150M 135M 124M 112M 210M 14.26B 214M 1.48B 592M 7.5B 564M 552M 23.66B
Projected Income Statement - Annual - Laboratorios Richmond S.A.C.I.F.
Logo Laboratorios Richmond S.A.C.I.F.
Laboratorios Richmond SACIF is an Argentina-based company, which is engaged in the development and manufacture of pharmaceuticals. The Company's product categories include: Antiviral, under the brands Ciganclor, Lazinevir, Leuzan, Mivuten, Probirase, Protease, Selmivir, Trivenz, Virontar, Virontar N, Virontar 600, Vuclodir, Zepril, Zetavudin, and Zetrotax; Oncologi and Oncohematologic, under the brands Bemux, Capecit, Doxetal, Drifen, Espasevit, Fontrax, Gezt, and Monofer, among others; Cardiovascular, under the brands Amze 5, Amze 10, Antiplaq, Bilip 10, Bilip 20, Tacardia, and Timezol 20, among others; Neuropsychiatric, under the brands Dalam 15, Dolofrix 10, Donepes 5, and Prilben 10, among others, as well as Hospital, under the brands Amidiaz, Dalam, and Fentax, among others.
Employees
620
Date Price Change Volume
30/10/26 ARS 1,305.00 +0.38% 693
29/10/26 ARS 1,300.00 -5.80% 982
28/10/26 ARS 1,380.00 +6.98% 784
27/10/26 ARS 1,290.00 -2.27% 993
26/10/26 ARS 1,320.00 -2.22% 407
  1. Stock Market
  2. Stocks
  3. RICH Stock